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Premature mortality in active convulsive
epilepsy in rural Kenya
Causes and associated factors
ABSTRACT
Objective: We estimated premature mortality and identified causes of death and associated factors
in people with active convulsive epilepsy (ACE) in rural Kenya.
Methods: In this prospective population-based study, people with ACE were identified in a cross-
sectional survey and followed up regularly for 3 years, during which information on deaths and
associated factors was collected. We used a validated verbal autopsy tool to establish putative
causes of death. Age-specific rate ratios and standardized mortality ratios were estimated. Pois-
son regression was used to identify mortality risk factors.
Results: Therewere 61 deaths among 754 people with ACE, yielding a rate of 33.3/1,000 persons/
year. Overall standardized mortality ratio was 6.5. Mortality was higher across all ACE age groups.
Nonadherence to antiepileptic drugs (adjusted rate ratio [aRR] 3.37), cognitive impairment (aRR
4.55), and age (501 years) (rate ratio 4.56) were risk factors for premature mortality. Most deaths
(56%) were directly related to epilepsy, with prolonged seizures/possible status epilepticus (38%)
most frequently associated with death; some of these may have been due to sudden unexpected
death in epilepsy (SUDEP). Possible SUDEP was the likely cause in another 7%.
Conclusion: Mortality in people with ACE was more than 6-fold greater than expected. This may
be reduced by improving treatment adherence and prompt management of prolonged seizures
and supporting those with cognitive impairment. Neurology® 2014;82:582–589
GLOSSARY
ACE 5 active convulsive epilepsy; AED 5 antiepileptic drug; aRR 5 adjusted rate ratio; CI 5 confidence interval; COD 5
cause of death; HIC5 high-income country; ICD-105 International Classification of Diseases, 10th revision; KHDSS5 Kilifi
Health and Demographic Surveillance System; LMICs 5 low- and middle-income countries; pyo 5 person-years of observa-
tion; SMR 5 standardized mortality ratio; SUDEP 5 sudden unexpected death in epilepsy.
Epilepsy is one of the most common noncommunicable neurologic conditions in the world, esti-
mated to affect approximately 70 million people, with up to 90% living in low- and middle-
income countries (LMICs).1 It is associated with premature mortality, 1.3–9.3 times that of
the background population in high-income countries (HICs) and much higher in institutionalized
people and those with cerebral malformations.2,3 In LMICs there are few data, which are based on
small cohorts with few deaths4–6 conducted in areas with high incidence of epilepsy5 that may not
be representative.
Risk factors for mortality in epilepsy in developed countries3,7,8 include age at onset, duration
of epilepsy (risk highest in the first 2 years after onset),3 high seizure frequency, convulsive
seizures,3 and remote symptomatic etiology.9,10 In LMICs, however, risk factors for death have
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only been reported from China and included
young age at onset of epilepsy, duration of
epilepsy, and living close to a body of water.11
Causes of death (CODs) in epilepsy,
including epilepsy-related CODs, have been
studied in HICs.7,12 In LMICs, cause-specific
mortality data are scant and have been
reported in only 2 countries: China, where
CODs included injuries and accidents, stroke,
status epilepticus, and suicide13,14; and Ethiopia,
where death was related to epilepsy.15,16
We used a population-based prospective
cohort study of people with active convulsive
epilepsy (ACE) in a resource-limited rural area
of Kenya to determine the magnitude of and
possible causes and risk factors associated with
mortality.
METHODS Study setting and study population. The
study setting and population characteristics have been described
previously.17–19 Briefly, the study was within the Kilifi Health
and Demographic Surveillance System (KHDSS) (http://www.
kemri-wellcome.org/khdss/) in the Kilifi District of Kenya. In
2008 there were 233,800 people in the study area.20 Households
were mapped using global positioning system, and maps were used
to locate and follow up participants. Field personnel conduct
re-enumeration and vital status updates of the population register
3 times per year.
About 80% of the population depends on subsistence farming
and the rest are engaged in casual and formal employment or infor-
mal trading. Approximately 55% live in poverty.
Identification and follow-up of cohorts of participants
with and without ACE. We used the International League
Against Epilepsy definitions of epilepsy21 but defined ACE as at
least one convulsive seizure in the preceding 12 months,22,23 as
this is the Kenyan criterion for offering antiepileptic treatment.24
We identified a cohort of people with ACE and the general
population (people without ACE) in a baseline 3-stage population-
wide prevalence screening between December 2007 and June
2008.19 In the first stage we asked household heads 2 questions to
identify members with a history of convulsions, who were followed up
with a more detailed epilepsy screening tool at a second stage. Those
positive were then evaluated by an epilepsy-specialized clinician and
the diagnoses were confirmed independently by a neurologic panel.
Those diagnosed, if not on antiepileptic drugs (AEDs), were offered
treatment. At this stage we collected clinical and demographic data
including age, sex, level of schooling and employment (for adults),
time (or age) of first seizure, and cognitive impairment (a clinician
assessed the individual’s response to questions [including orientation
to person, place, and time] and ease of following instructions).
We followed up the identified ACE cohort every 3 months in
the study clinic for dose adjustments, assessment of adverse
events, monitoring adherence, and to replenish supplies of AEDs.
Those who did not attend the clinic appointments were followed
up in the community within 2 weeks by a fieldworker. During
each review we administered a questionnaire to capture demo-
graphic information and potential risk factors for mortality.
If a member of the ACE cohort was not on treatment during
one of the appointments, we classified him or her as nonadherent
to AEDs as, by definition, he or she had active epilepsy. This was
determined by asking to see the medication during all visits in the
community or if they missed a clinic appointment and were not
taking AEDs at the subsequent attendance.
We followed up the general population for vital status and
migration during the routine re-enumeration within the KHDSS.
Participants were followed up until death or the end of the study
or were censored at out-migration (and during the last clinic con-
tact or withdrawal of consent/refusal for people with ACE).
Postmortem examinations, which are the gold standard for
the determination of COD, are not conducted in this rural area.20,25
To determine putative COD, we investigated the immediate
CODs using the World Health Organization verbal autopsy tool
(appendix e-1 on the Neurology® Web site at www.neurology.org)
administered by a fieldworker trained in the sensitivity required to
interview bereaved relatives. We were unable to examine death
certificates as these, in keeping with local tradition, are destroyed
with all personal effects of the deceased after the funeral (Francis
Yaa, oral communication, October 12, 2012).
We conducted the verbal autopsy interviews within 1–4
months of death to allow for the culturally acceptable mourning
period in this community. As much as possible we interviewed
either the guardian or the carer of the deceased prior to death. The
CODs were assigned independently by 3 clinicians trained in the
use of the ICD-10. We considered the assigned COD as final if
there was agreement between all coders. A fourth coder (C.R.N.)
independently assigned COD in instances where initially an
agreement could not be reached. Disagreements between the 4
coders were resolved by consensus, or the cause was designated as
unclassified.
Statistical analysis. We estimated mortality rates as the number
of deaths divided by the total person-years of observation. To
compare mortality between people with ACE and the general
population, mortality in those with ACE was stratified in age
bands and standardized mortality ratios (SMRs) were estimated
using the age-specific rates of the general population. We
performed a sensitivity analysis on the rate ratio to determine
whether it was sensitive to losses to follow-up; the mortality
rates in both the “lost” cases and the “lost” general population
varied between 0.5 and 3 times the observed rates. Excess death
rates were estimated as the absolute age-specific rate differences
between the ACE and general population groups.
We used Poisson regression to examine the influence of 10
putative risk factors on mortality in the ACE cohort. We deter-
mined these at baseline (sex, age at onset, schooling, distance to
health facilities, duration of epilepsy, income, and cognitive
impairment) and/or during each of the 3-month reviews (seizure
frequency, adherence to AEDs, and current age). The last 3 var-
iables were modeled as time-dependent covariates.
In the multivariable analysis we explored the relationship
between mortality and 1) AED adherence, 2) cognitive impair-
ment, 3) schooling, and 4) age at onset, as these were significant
in the univariable analysis.
The relationships of putative COD to ACE were categorized
independently by 2 clinicians as 1) directly or indirectly related to
epilepsy, 2) related to the underlying cause of epilepsy, 3) not
related to epilepsy, or 4) unknown. Epilepsy-related CODs were
defined as 1) death during a prolonged seizure–possible status
epilepticus; 2) sudden death in epilepsy (possible sudden unex-
pected death in epilepsy [SUDEP])–sudden unwitnessed death or
death without any preceding illness; or 3) death following a
seizure-related accident, e.g., drowning, falling from heights.
We also estimated cause-specific mortality proportions and com-
pared the epilepsy-specific mortality proportions to the
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attributable fraction (12 (1/rate ratio)) to determine the perfor-
mance of the verbal autopsy in capturing epilepsy-related mortality.
All analyses were carried out in STATA v. 11 (StataCorp,
College Station, TX).
Standard protocol approvals, registrations, and patient
consents. We obtained written informed consent from all partic-
ipants. When the person with ACE was a child, an adult who
could not respond, or had died, a guardian/carer was interviewed.
Approval for the study was obtained from the Kenya Medical
Research Institute/National Ethical Review Committee.
RESULTS At study start in December 2007, 232,164
participants entered the cohorts: 754 individuals with
ACE and 231,410 people in the general population
(without ACE) (table 1). The median (interquartile
range) follow-up for people with ACE was 32.6
(27.7–41.1) months and for the general population
was 32.6 (28.5–32.6) months. Within the ACE
group we recorded a total of 7,331 contacts with a
median of 11 follow-up contacts per person. We
recorded 61 deaths in people with ACE and 3,291
in the general population at study end in November
2011. Outcomes by ACE status are shown in table 1.
Among people with ACE, loss to follow-up did not
vary by age group (p 5 0.906), sex (p 5 0.126), or
school attendance (p 5 0.061) of the participant.
The total person-years of observation (pyo) was
1,833 for the ACE cohort and 540,909 for the general
population, with crude mortality rates of 33.3/1,000
pyo (95% confidence interval [CI]: 25.9–42.8) and
6.1/1,000 pyo (95% CI: 5.9–6.3), respectively. The
crude rate ratio was 5.5 (95% CI: 4.2–7.0) and the
SMR was 6.5 (95% CI: 5.0–8.3). In the sensitivity
analyses, overall mortality rate ratios varied between
3.2 and 7.9 (table e-1). Mortality was higher than in
the general population in all age groups: age-specific
rate ratios ranged from 4.4 (95% CI: 1.1–17.4) in
the 0 to 5 years age group to 22.5 (95% CI: 12.5–
40.6) in the 6 to 12 years age group. The excess death
rate per 1,000 pyo increased with age, ranging from
14.4 in 0- to 5-year-olds to 55.3 in those aged $50
years (table e-2).
In the univariable analysis, current age, age at
onset of seizures, AED nonadherence, and cognitive
impairment were associated with mortality. Having
attended school was protective against mortality
(table 2). After adjusting for potential confounding,
those not taking AEDs (rate ratio 3.37 [95% CI:
1.84–6.16]) and those with cognitive impairment
(rate ratio 4.55 [2.49–8.33]) were at higher risk (table 3).
Epilepsy-related deaths were also associated with not tak-
ing AEDs (adjusted rate ratio [aRR] 3.41 [1.57–7.42])
and cognitive impairment (aRR 4.34 [2.51–8.76])
(table e-3).
More than half (56%) of the putative CODs in
the population with ACE were directly or indirectly
related to epilepsy. Most deaths (38%) occurred dur-
ing a prolonged seizure (possible status epilepticus)
and about 7% (n 5 4) were possible SUDEP. About
40% of the CODs were either unrelated to epilepsy
or unknown (table 4). The frequency of epilepsy-
related COD was higher (52% of total deaths) in
those aged 19–49 years than in those younger than
19 years (35%) or the elderly (43%). Cardiovascular-
related CODs were significant in the $50-year-olds
(table 5).
The overall attributable fraction for ACE was 82%
and was highest (.90%) in the 6 to 28 years age
groups (table e-2).
DISCUSSION Mortality in people with ACE in this
population was 6 times higher than that of the general
population, and this was higher than that reported in
other studies from LMICs.13,14 The high mortality
rate in our study (compared to other studies that
reported rates from 0.024 to 16.4/1,000 pyo26–29)
may be partly due to the fact that we assessed only
convulsive epilepsy, which is usually associated with
higher mortality than nonconvulsive epilepsies.3,7
The inclusion of only those with a seizure within
the preceding year formed a group with more severe
epilepsy than is usually included in epidemiologic
studies of active epilepsy (seizures within the last
5 years) and could also have contributed to the high
mortality.
The highest age-specific mortality rate ratio was in
the 6–28 years age group, which also had the lowest
mortality rate in the general population. In Ugandan
and Chinese studies relative mortality was also highest
in this age group.5,13 Mortality in this age group could
result from remote symptomatic epilepsy,9,10 from
etiologies occurring earlier in life (e.g., infections of
the brain, cerebral palsy), or from the higher risk of
head injuries. The epilepsy-related mortality in these
ages could also be due to difficulties in adherence to
AEDs, SUDEP, or recent onset of seizures.3,10 The
lower rate ratios in the other age groups may reflect
the relatively higher mortality rates seen in the corre-
sponding age groups in the general population. Pre-
vious studies in Kilifi suggest that mortality in these
Table 1 Follow-up of study participants with active convulsive epilepsy (ACE)
and the general population in Kilifi, Kenya
Status General population, n (%) ACE, n (%) Total
Moved 70,339 (30.4) 49 (6.5) 70,388
Not found 92 (0.04) 15 (2.0) 107
Refused 0 (0.0) 23 (3.1) 23
Died 3,291 (1.4) 61 (8.1) 3,352
Completed 157,688 (68.1) 606 (80.4) 158,294
Total 231,410 (100.0) 754 (100.0) 232,164
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Table 2 Univariable analysis of factors associated with mortality in people with active convulsive epilepsy in
Kilifi, Kenya
Factor Person-years Deaths Mortality rate (95% CI) Rate ratio (95% CI) p Value
Current age, y
0–5 162 3 18.6 (6.0–57.6) 1.00 (NA)
6–12 392 7 17.8 (8.5–37.4) 0.96 (0.25–3.71)
13–18 307 7 22.8 (10.9–47.8) 1.23 (0.32–4.75)
19–28 520 18 34.7 (21.8–52.0) 1.87 (0.55–6.33) 0.01
29–49 287 12 41.9 (23.8–73.7) 2.25 (0.64–7.98)
501 165 14 84.7 (50.2–143.1) 4.56 (1.31–15.87)
Age at onset, y
0–5 1,108 26 23.5 (16.0–34.5) 1.00 (NA)
6–12 278 10 36.0 (19.4–66.9) 1.53 (0.74–3.02)
13–18 170 8 47.1 (23.5–94.1) 2.00 (0.91–4.43)
19–28 110 2 18.1 (4.5–72.5) 0.77 (0.18–3.26) ,0.001
29–49 75 3 40.0 (12.9–124.0) 1.70 (0.52–5.63)
501 92 12 130.4 (74.1–229.7) 5.56 (2.80–11.01)
Sex
Female 882 32 36.3 (25.7–51.3) 1.00 (NA)
Male 951 29 30.5 (21.2–43.9) 0.84 (0.51–1.39) 0.48
Schooling
No 909 39 42.9 (31.4–58.7) 1.00 (NA)
Yes 924 22 23.8 (15.7–36.2) 0.56 (0.33–0.94) 0.03
Distance to health facility, km
<10 589 19 32.3 (20.6–50.6) 1.00 (NA)
10–19 654 20 30.6 (19.7–47.4) 0.95 (0.50–1.77)
20–30 471 18 38.2 (24.1–60.7) 1.18 (0.62–2.26) 0.92
>30 119 4 33.6 (12.6–89.6) 1.04 (0.35–3.06)
Earns an incomea
No 520 28 53.8 (37.2–78.0) 1.00 (NA)
Yes 285 9 31.6 (16.4–60.7) 0.59 (0.28–1.24) 0.16
Duration of epilepsy, y
<1 175 8 45.9 (22.9–91.7) 1.00 (NA)
1–5 553 17 30.8 (19.1–49.5) 0.67 (0.29–1.56)
6–10 334 12 35.9 (20.4–63.2) 0.78 (0.32–1.92) 0.78
>10 771 24 31.1 (20.9–46.4) 0.68 (0.30–1.51)
Seizure frequency
None/mo 1,177 37 31.4 (22.8–43.4) 1.00 (NA)
‡1/mo 656 24 35.3 (24.5–54.6) 1.16 (0.70–1.94) 0.56
Cognitive impairment
No 1,322 28 21.2 (14.6–30.7) 1.00 (NA)
Yes 511 33 64.6 (46.0–90.9) 3.05 (1.84–5.05) ,0.001
Adherent to AEDs
Yes 870 14 16.1 (9.5–27.2) 1.00 (NA)
No 963 47 48.8 (36.7–65.0) 3.14 (1.72–5.63) ,0.001
Abbreviations: AED 5 antiepileptic drug; CI 5 confidence interval; NA 5 not applicable.
aAnalysis performed only in adults (.18 years).
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age groups is related to perinatal, nutritional, and
infectious causes in the very young30,31 and HIV-
related and cardiovascular causes in the older age
groups.25 In our study, prolonged seizures (possible
status epilepticus) were the most important cause of
death in people with epilepsy. In China, status epi-
lepticus and drowning were significant.11 These stud-
ies highlight the importance of seizure control in
preventing mortality.
Excess mortality increased with age and it is likely
that recurrent seizures in the old aggravate the severity
of coexisting conditions (e.g., cardiovascular disease).
The attributable fraction (82%) was higher than the
epilepsy-specific mortality proportion determined
through verbal autopsy (55.7%), suggesting that
some of the epilepsy-related deaths may have been
misclassified. Alternatively, the attributable fraction
estimate could have been confounded by factors such
as poverty or infectious diseases.
In the univariable analysis, those who were nonad-
herent to AEDs and/or who had cognitive impairment
were at higher risk of mortality. In the adjusted analy-
sis, those not on AEDs had a 3-fold increased risk com-
pared to those on at least one AED. This association is
important in view of the large treatment gap (62%)
reported in Kilifi32 and the fact that epilepsy-related
CODs, particularly prolonged seizures, were the most
important in this population. Our findings are similar
to those of a British study33 but dissimilar to those of a
Ugandan study,5 which did not find higher mortality
among people who were not adherent. Possible reasons
for the difference include the fact that the Ugandan
study was relatively small (61 patients) and used self-
reported adherence, which has low sensitivity.32 Adher-
ence in that study was assessed at only 2 time points
over a 6-year period in a lifetime epilepsy cohort, in
which some cases could have entered remission. Non-
adherence leads to poorly controlled seizures, which
may increase epilepsy severity (with respect to duration
of seizures) and thus impart higher risk of epilepsy-
related mortality. Poor seizure control may also
increase seizure risk in hazardous environments, caus-
ing death by accidents (e.g., drowning and falling from
heights). Age at onset and duration of ACE, which
were associated with mortality in China,11 were not
significant in our study possibly because the Chinese
study investigated associations with specific causes of
death (e.g., status epilepticus or drowning). Cognitive
impairment is likely to increase the risk of mortality
through injury resulting from seizures in risky environ-
ments, particularly if individuals are not supervised.
Cognitive impairment is also likely to be a marker of
more severe epileptic encephalopathies (e.g., Lennox-
Gastaut syndrome in children), which confer a higher
risk of premature mortality than more benign
syndromes.34
This high risk of epilepsy-related mortality high-
lights the need to prevent seizures and reduce risk fac-
tors for mortality. Risk factors for epilepsy such as
adverse perinatal events and parasitic infections
should be targeted.19 Education of patients and carers
on the importance of treatment and adherence to
medication and monitoring and supporting people
with cognitive impairment (e.g., assigning a house-
hold member as a designated helper) could reduce the
risks associated with epilepsy-related causes of death.
Additionally, AEDs that are effective against more
severe epilepsy syndromes associated with cognitive
impairment should be availed at the primary care
level, although this is likely to have considerable
resource implications. Factors associated with nonad-
herence in this population include long distances to
AED distribution points and traditional animistic
beliefs about epilepsy.32 Increasing access to AEDs
by ensuring adequate supply at the primary care level
Table 3 Adjusted rate ratios for mortality in people with active convulsive
epilepsy in Kilifi, Kenya
Factor Rate ratio (95% CI) p Value
Current age, y (unadjusted)
0–5 1.00 (NA)
6–12 0.96 (0.25–3.71)
13–18 1.23 (0.32–4.75)
19–28 1.87 (0.55–6.33) 0.01
29–49 2.25 (0.64–7.98)
501 4.56 (1.31–15.87)
Age at onset,a y
0–5 1.00 (NA)
6–12 1.34 (0.63–32.85)
13–18 1.53 (0.67–3.54)
19–28 0.53 (0.12–2.39) 0.27
29–49 1.28 (0.29–5.62)
501 5.25 (0.85–32.43)
Schoolingb
No 1.00 (NA)
Yes 0.83 (0.47–1.44) 0.50
Cognitive impairmentc
No 1.00 (NA)
Yes 4.55 (2.49–8.33) ,0.001
Adherent to AEDsd
Yes 1.00 (NA)
No 3.37 (1.84–6.16) ,0.001
Abbreviations: AED 5 antiepileptic drug; CI 5 confidence interval; NA 5 not applicable.
a Adjusted for current age.
bAdjusted for age at onset, current age, and cognitive impairment.
c Adjusted for age at onset, current age, and schooling.
dAdjusted for current age, cognitive impairment, and schooling.
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and creation of awareness about treatment may well
lead to a significant reduction in premature mortality.
We had large attrition of people without ACE,
mainly out-migrants. Due to cost and logistical impli-
cations, we did not determine their survivorship status,
although their demographic characteristics were not
significantly different from those in the study. Mortal-
ity rate ratios, however, were more than 3 even after
sensitivity analysis.
We used a prevalence cohort, which might under-
estimate short-termmortality due to the early mortality
of people with severe ACE. A prospectively identified
population-based cohort of incident cases may provide
more accurate ratios but would be more expensive.
We were unable to estimate cause-specific SMRs
due to lack of cause-specific mortality data in the gen-
eral population. We did not use a validated tool to
screen for cognitive impairment, and it is likely we
included only those with the most severe form, hence
the strong association with premature mortality.
As is common inmany resource-poor settings, post-
mortem examination, the gold standard for identifying
Table 4 Causes of death in people with active convulsive epilepsy in Kilifi, Kenya
Related to epilepsy Unrelated to epilepsy/undetermined
COD No. (PMR %)a COD No. (PMR %)
Directly related Cardiovascular/stroke
Possible status epilepticus/prolonged seizures 23 (37.7) 3 (4.9)
Possible SUDEP 4 (6.6) Pneumonia 1 (1.6)
Indirectly related Meningitis 3 (4.9)
Tuberculosis 1 (1.6)
Fall from heights 2 (3.3) Malaria 1 (1.6)
Drowning 2 (3.3) Septicemia 1 (1.6)
Traffic accidents 1 (1.6) Diabetes mellitus 2 (3.3)
Aspiration pneumonia 1 (1.6) Otherb 9 (14.8)
Burns 1 (1.6) Undetermined 6 (9.8)
Total 34 (55.7) 27 (44.3)
Abbreviations: COD 5 cause of death; PMR 5 proportional mortality rate; SUDEP 5 sudden unexpected death in epilepsy.
a PMR refers to the percentage of all deaths attributed to a particular cause.
b Including anemia, gastroenteritis, hemorrhage, hepatitis, hydrocephalus, injuries from assault, kwashiorkor, and
shigellosis.
Table 5 Age-specific proportional mortality in people with active convulsive epilepsy in Kilifi, Kenya
Age group at death, y
COD 0–18 19–49 501 Total
Directly related to epilepsy
Possible status epilepticus/prolonged seizures 6 (30.0) 11 (40.7) 6 (42.9) 23 (37.7)
Possible SUDEP 1 (5.0) 3 (11.1) 0 (0.00) 4 (6.6)
Indirectly related to epilepsy
Injury/accident and related causes 2 (10.0) 4 (14.8) 1 (7.1) 7 (11.5)
All others
Stroke 0 (0.00) 0 (0.00) 1 (7.1) 1 (1.7)
Cardiovascular 0 (0.00) 0 (0.00) 2 (14.3) 2 (3.3)
Infectious causes 4 (20.0) 5 (18.5) 0 (0.00) 9 (14.8)
Othera 4 (20.0) 4 (14.8) 1 (7.1) 9 (14.8)
Undetermined 3 (15.0) 1 (3.7) 2 (14.3) 6 (9.8)
Total 20 (100.0) 27 (100.0) 14 (100.0) 61 (100.0)
Abbreviations: COD 5 cause of death; PMR 5 proportional mortality rate; SUDEP 5 sudden unexpected death in epilepsy.
Data are presented as n (PMR %).
a Including anemia, diabetes mellitus, hemorrhage, hydrocephalus, injuries from assault, and kwashiorkor.
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COD, was unavailable. The use of death certificates in
epilepsy, however, is fraught with problems, since epi-
lepsy is only attributed as a COD when seizure-related
clinical events are observed immediately preceding
death.35 To overcome this, we carried out verbal autop-
sies and CODs were attributed by moderation based
on the verbal autopsies. CODs should therefore be
considered putative rather than definitive. We were,
for instance, unable to establish definite status epilep-
ticus as a COD in people who died during prolonged
seizures since this was a population-based study in
which terminal seizure events were not timed and were
dependent on recall by witnesses. There is therefore a
likelihood of overlap between possible SUDEP and
prolonged seizures.
It is likely that certain epilepsy syndromes and sei-
zure types are associated with mortality in people with
epilepsy. However, we were unable to determine spe-
cific seizure types (other than convulsive), epilepsy
syndrome, or etiology in this cohort due to limited
seizure type information during follow-up.
Our findings highlight the urgency of prioritizing
epilepsy as a major public health problem. Increased
resources need to be allocated to improve access to
and utilization of diagnostic, treatment, and preven-
tive services. The health system needs to increase
and sustain capacity to provide appropriate health
services to people with epilepsy at the primary care
level (e.g., in terms of training and retaining nurses
or clinical officers to diagnose and manage epilepsy
as well as provide AEDs). Preventive interventions
must be given priority, with the identification of pre-
ventable causes in communities as well as risk factors
of mortality in epilepsy through deployment of meas-
ures such as health education and promotion.
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